leisure time -WSS

leisure time

author：leisure time 2025-09-30 18:34:50 - browse：5

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Emergency workers more likely to restrain Black patients: study

WSS

'CMA Fest' 2023: How to watch, who is performing and more

There’s a way to spot data fakery. All journals should be using it

Readout LOUD podcast: possible new ALS drug, artificial wombs

EpiPen alternative approval delay highlights citizen petition issue

Intarcia’s device

Stanford president’s abrupt resignation sparks debate

Wikipedia

leisure time

entertainment

At least 13 dead in Texas as scorching temps continue

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Medicare details structure of new drug price negotiation program

What Congress can do to address the rural doctor shortage

As demand for Covid shots wanes, Moderna seeks its next success

Extensive review finds private equity owners jack up cost of care

Novavax promises a turnaround & Lilly roils the obesity market

Senate HELP committee spars over health care workforce policies

The high cost of giving birth even with insurance

Readout LOUD podcast: possible new ALS drug, artificial wombs

focus

Hearing on Medicare drug price negotiation gets unusually heated

In rare move, senator releases unverified FBI source report alleging Biden bribe

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Sanders wants to replace patents with prizes for drug inventions

A new ‘biological computer' targets cancer while sparing healthy cells

Thermo Fisher plant for manufacturing gene therapies to expand

hotspot

Wikipedia

hotspot

Wikipedia